DGX Stock Outlook 2026: Quest Diagnostics as a Defensive Value Play
Quest Diagnostics (DGX) offers infrastructure-scale defensiveness in clinical lab testing, but PAMA reimbursement headwinds and margin limits cap upside. A frank 2026 analysis.
DGX Quest Diagnostics lab testing